Dose Escalated Radiotherapy for Rectal Cancers Using MR-guided Radiotherapy

Standard radiotherapy in the UK involves having daily chemotherapy tablets with radiotherapy treatment for 5 weeks at a dose of 52.5Gy to the rectal cancer over 25 fractions. This is the likely treatment participants will be having if they decide not to take part in this study. Increasing the dose to 60Gy is shown to increase the chance that rectal cancer will be treated completely, a term known as "complete pathological response". Patients who have a complete pathological response after their treatment can avoid surgery and enter into a surveillance programme to monitor for early signs of the

Trial Details

NCT ID
NCT06854679
Phase
NA
Sponsor
Royal Marsden NHS Foundation Trust
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Radiotherapy dose escalation
Locations (sample)
  • Sutton, Surrey, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • All patients aged ≥18 years
  • Histological confirmation of locally advanced rectal adenocarcinoma requiring neoadjuvant chemoradiotherapy as per RMH clinical guidelines.
  • Patients suitable for concomitant chemotherapy
  • Patients with disease included within treatment field size of MR-Linac.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →